<div><div></div><div><span><p><span>Dinesh V. Patel, a director and President, CEO, reported the direct sale of common stock at a weighted average price of $100.12 per share. The total proceeds from the sale were $7,509,000. Following the transaction, Patel directly owned 523,478 shares of common stock. The price reported represents the weighted average sale price; shares were sold in multiple transactions at prices ranging from $98.83 to $103.50.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Patel Dinesh V Ph D</span></td></tr><tr><td><span>Relationship</span></td><td><span>President and CEO</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$7,509,000</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

PTGX

SBIO

ARKG

LABU

<p>Dinesh V. Patel, President and CEO of Protagonist Therapeutics, sold shares worth $7.5 million at an average price of $100.12 per share. Following the sale, he retains ownership of 523,478 shares. The sale involved multiple transactions with prices ranging from $98.83 to $103.50, as reported in SEC Form 4 filings.</p>

TradingView

Protagonist Therap

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M